基于脑脊液甲基化组的液体活检用于恶性脑肿瘤精准分类
本研究利用57例脑转移瘤、胶质母细胞瘤、中枢神经系统淋巴瘤及非肿瘤对照患者的脑脊液甲基化组构建肿瘤类型分类器,在独立验证集中脑转移瘤AUROC为0.93(95%CI 0.71-1.0)、胶质母细胞瘤为0.83(95%CI 0.63-1.0)、中枢神经系统淋巴瘤为0.91(95%CI 0.66-1.0),并利用197例公共组织甲基化谱进行验证与模型优化,表明脑脊液甲基化组可用于上述三类恶性脑肿瘤的液体活检分类。
要点
- 脑脊液甲基化组分类器可区分脑转移瘤、胶质母细胞瘤与中枢神经系统淋巴瘤。
- 独立验证集AUROC:脑转移瘤0.93、胶质母细胞瘤0.83、中枢神经系统淋巴瘤0.91。
- 脑脊液甲基化信号与对应肿瘤组织甲基化特征高度一致。
核心结论
- 脑脊液甲基化组可可靠地用于三大恶性脑肿瘤类型的液体活检分类。
研究设计与样本
- 研究纳入57例脑转移瘤、胶质母细胞瘤、中枢神经系统淋巴瘤及非肿瘤对照患者,获取脑脊液甲基化组。
- 在50次迭代中,每次以80%样本为发现集构建肿瘤类型的二项GLMnet分类器,其余20%为独立验证集。
- 利用197例公共组织甲基化谱(涵盖上述肿瘤实体及正常脑实质)进行验证和模型优化。
主要发现
- 独立20%验证集中,模型区分脑转移瘤的AUROC为0.93(95%CI 0.71-1.0)。
- 独立20%验证集中,模型区分胶质母细胞瘤的AUROC为0.83(95%CI 0.63-1.0)。
- 独立20%验证集中,模型区分中枢神经系统淋巴瘤的AUROC为0.91(95%CI 0.66-1.0)。
- 基于脑脊液的甲基化特征可区分外部组织样本中的肿瘤类型,并在脑脊液和组织中区分肿瘤与非肿瘤对照。
- 脑脊液甲基化信号与各肿瘤实体的组织甲基化特征高度一致。
临床怎么用
- 作者讨论液体活检未来可能通过避免手术风险、对无法活检的肿瘤进行分类以及在需要切除时指导手术规划来影响脑肿瘤管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resolving the differential diagnosis between brain metastases (BM), glioblastomas (GBM), and central nervous system lymphomas (CNSL) is an important dilemma for the clinical management of the main three intra-axial brain tumor types. Currently, treatment decisions require invasive diagnostic surgical biopsies that carry risks and morbidity. This study aimed to utilize methylomes from cerebrospinal fluid (CSF), a biofluid proximal to brain tumors, for reliable non-invasive classification that addresses limitations associated with low target abundance in existing approaches. METHODS: Binomial GLMnet classifiers of tumor type were built, in fifty iterations of 80% discovery sets, using CSF methylomes obtained from 57 BM, GBM, CNSL, and non-neoplastic control patients. Publicly-available tissue methylation profiles (N = 197) on these entities and normal brain parenchyma were used for validation and model optimization. RESULTS: Models reliably distinguished between BM (area under receiver operating characteristic curve [AUROC] = 0.93, 95% confidence interval [CI]: 0.71-1.0), GBM (AUROC = 0.83, 95% CI: 0.63-1.0), and CNSL (AUROC = 0.91, 95% CI: 0.66-1.0) in independent 20% validation sets. For validation, CSF-based methylome signatures reliably distinguished between tumor types within external tissue samples and tumors from non-neoplastic controls in CSF and tissue. CSF methylome signals were observed to align closely with tissue signatures for each entity. An additional set of optimized CSF-based models, built using tumor-specific features present in tissue data, showed enhanced classification accuracy. CONCLUSIONS: CSF methylomes are reliable for liquid biopsy-based classification of the major three malignant brain tumor types. We discuss how liquid biopsies may impact brain cancer management in the future by avoiding surgical risks, classifying unbiopsiable tumors, and guiding surgical planning when resection is indicated.
引用
- Zuccato JA, Patil V, Mansouri S, et al. Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification. Neuro Oncol. 2023. PMID: 36455236. doi:10.1093/neuonc/noac264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。